Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 358 articles:
HTML format
Text format



Single Articles


    August 2017
  1. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  2. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  3. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  4. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  5. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  6. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  7. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  8. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  9. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  10. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  11. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  12. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  13. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  14. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  15. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  16. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  17. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


    July 2017
  18. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Text format     Abstract available


    June 2017
  19. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Text format     Abstract available


  20. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Text format     Abstract available


  21. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Text format     Abstract available


  22. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Text format     Abstract available


  23. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Text format     Abstract available


  24. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed     Text format    


  25. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Text format     Abstract available


  26. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Text format     Abstract available


  27. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Text format     Abstract available


  28. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed     Text format    


  29. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed     Text format    


  30. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Text format     Abstract available


  31. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Text format     Abstract available


  32. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Text format     Abstract available


  33. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Text format     Abstract available


    May 2017
  34. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Text format     Abstract available


  35. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Text format     Abstract available


  36. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Text format     Abstract available


  37. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Text format     Abstract available


  38. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Text format     Abstract available


  39. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Text format     Abstract available


  40. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Text format     Abstract available


  41. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Text format     Abstract available


  42. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Text format     Abstract available


  43. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Text format     Abstract available


  44. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Text format     Abstract available


  45. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Text format     Abstract available


  46. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Text format     Abstract available


  47. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Text format     Abstract available


  48. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Text format     Abstract available


  49. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Text format     Abstract available


  50. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Text format     Abstract available


  51. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Text format     Abstract available


  52. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Text format     Abstract available


  53. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Text format     Abstract available


  54. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Text format     Abstract available


  55. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Text format     Abstract available


    April 2017
  56. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed     Text format    


  57. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Text format     Abstract available


  58. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Text format     Abstract available


  59. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Text format     Abstract available


  60. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Text format     Abstract available


  61. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Text format     Abstract available


  62. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Text format     Abstract available


  63. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Text format     Abstract available


  64. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Text format     Abstract available


  65. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Text format     Abstract available


  66. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Text format     Abstract available


  67. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Text format     Abstract available


  68. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Text format     Abstract available


  69. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Text format     Abstract available


  70. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Text format     Abstract available


  71. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed     Text format    


  72. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Text format     Abstract available


  73. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Text format     Abstract available


    March 2017
  74. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Text format     Abstract available


  75. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Text format     Abstract available


  76. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed     Text format    


  77. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed     Text format    


  78. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Text format     Abstract available


  79. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Text format     Abstract available


  80. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Text format     Abstract available


  81. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available


  82. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available


  83. WATTJES MP, Warnke C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.
    Mult Scler. 2017 Mar 1:1352458516685170. doi: 10.1177/1352458516685170.
    PubMed     Text format    


  84. YAP SM, McGuigan C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Mult Scler. 2017 Mar 1:1352458517697909. doi: 10.1177/1352458517697909.
    PubMed     Text format    


  85. ENZINGER C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
    Mult Scler. 2017 Mar 1:1352458516681505. doi: 10.1177/1352458516681505.
    PubMed     Text format    


  86. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Text format     Abstract available


  87. BEBO BF JR, Fox RJ, Lee K, Utz U, et al
    Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.
    Mult Scler. 2017 Mar 1:1352458517698250. doi: 10.1177/1352458517698250.
    PubMed     Text format     Abstract available


  88. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Text format     Abstract available


  89. ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
    Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
    PubMed     Text format     Abstract available


  90. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Text format     Abstract available


  91. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Text format     Abstract available


  92. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Text format     Abstract available


  93. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed     Text format    


  94. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed     Text format    


  95. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Text format     Abstract available


  96. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Text format     Abstract available


    February 2017
  97. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Text format     Abstract available


  98. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Text format     Abstract available


  99. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Text format     Abstract available


  100. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Text format     Abstract available


  101. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed     Text format    


  102. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Text format     Abstract available


  103. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Text format     Abstract available


  104. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Text format     Abstract available


  105. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Text format     Abstract available


  106. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Text format     Abstract available


  107. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed     Text format    


  108. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Text format     Abstract available


  109. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed     Text format    


  110. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Text format     Abstract available


  111. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Text format     Abstract available


  112. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Text format     Abstract available


  113. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Text format     Abstract available


  114. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Text format     Abstract available


  115. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Text format     Abstract available


  116. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Text format     Abstract available


  117. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Text format     Abstract available


  118. BARCELLOS LF, Bellesis KH, Shen L, Shao X, et al
    Remote assessment of verbal memory in MS patients using the California Verbal Learning Test.
    Mult Scler. 2017 Feb 1:1352458517694087. doi: 10.1177/1352458517694087.
    PubMed     Text format     Abstract available


  119. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Text format     Abstract available


  120. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Text format     Abstract available


  121. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Text format     Abstract available


  122. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Text format     Abstract available


  123. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Text format     Abstract available


  124. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Text format     Abstract available


    January 2017
  125. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Text format     Abstract available


  126. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Text format     Abstract available


  127. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Text format     Abstract available


  128. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Text format     Abstract available


  129. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Text format     Abstract available


  130. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Text format     Abstract available


  131. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Text format     Abstract available


  132. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Text format     Abstract available


  133. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Text format     Abstract available


  134. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Text format     Abstract available


  135. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Text format     Abstract available


  136. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Text format     Abstract available


    December 2016
  137. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Text format     Abstract available


  138. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Text format     Abstract available


  139. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Text format     Abstract available


  140. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Text format     Abstract available


  141. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Text format     Abstract available


  142. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Text format     Abstract available


  143. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Text format     Abstract available


  144. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed     Text format    


    November 2016
  145. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Text format     Abstract available


  146. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Text format     Abstract available


  147. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Text format     Abstract available


  148. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Text format     Abstract available


  149. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Text format     Abstract available


  150. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Text format     Abstract available


  151. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Text format     Abstract available


  152. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Text format     Abstract available


  153. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Text format     Abstract available


  154. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Text format     Abstract available


  155. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Text format     Abstract available


  156. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Text format     Abstract available


  157. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Text format     Abstract available


  158. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Text format     Abstract available


  159. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed     Text format    


  160. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Text format     Abstract available


  161. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Text format     Abstract available


    October 2016
  162. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Text format     Abstract available


  163. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Text format     Abstract available


  164. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Text format     Abstract available


  165. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Text format     Abstract available


  166. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Text format     Abstract available


  167. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Text format     Abstract available


  168. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Text format     Abstract available


  169. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Text format     Abstract available


  170. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Text format     Abstract available


  171. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed     Text format    


    September 2016
  172. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Text format     Abstract available


  173. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Text format     Abstract available


  174. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Text format     Abstract available


  175. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Text format     Abstract available


  176. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Text format     Abstract available


  177. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Text format     Abstract available


  178. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Text format     Abstract available


  179. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed     Text format    


  180. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Text format     Abstract available


  181. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Text format     Abstract available


  182. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Text format     Abstract available


  183. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Text format     Abstract available


  184. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Text format     Abstract available


  185. GRYTTEN N, Skar AB, Aarseth JH, Assmus J, et al
    The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.
    Mult Scler. 2016 Sep 6. pii: 1352458516667240.
    PubMed     Text format     Abstract available


  186. TOURBAH A, Lebrun-Frenay C, Edan G, Clanet M, et al
    MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Mult Scler. 2016 Sep 1. pii: 1352458516667568.
    PubMed     Text format     Abstract available


  187. MUKHOPADHYAY S, Fellows K, Browne RW, Khare P, et al
    Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.
    Mult Scler. 2016 Sep 1. pii: 1352458516666187.
    PubMed     Text format     Abstract available


    August 2016
  188. TROJAN DA, Cybulsky AV
    Drinking away fatigue in multiple sclerosis.
    Mult Scler. 2016 Aug 19. pii: 1352458516666337.
    PubMed     Text format    


  189. CINCOTTA MC, Engelhard MM, Stankey M, Goldman MD, et al
    Fatigue and fluid hydration status in multiple sclerosis: A hypothesis.
    Mult Scler. 2016 Aug 19. pii: 1352458516663854.
    PubMed     Text format     Abstract available


  190. MATHIAS A, Perriard G, Canales M, Soneson C, et al
    Increased ex vivo antigen presentation profile of B cells in multiple sclerosis.
    Mult Scler. 2016 Aug 8. pii: 1352458516664210.
    PubMed     Text format     Abstract available


  191. LANZA G, Ferri R, Bella R, Ferini-Strambi L, et al
    The impact of drugs for multiple sclerosis on sleep.
    Mult Scler. 2016 Aug 8. pii: 1352458516664034.
    PubMed     Text format     Abstract available


  192. KHAN O, Rieckmann P, Boyko A, Selmaj K, et al
    Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Mult Scler. 2016 Aug 8. pii: 1352458516664033.
    PubMed     Text format     Abstract available


  193. KIM HJ, Lee J
    Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder'.
    Mult Scler. 2016 Aug 5. pii: 1352458516662730.
    PubMed     Text format    


  194. POMPA A, Morone G, Iosa M, Pace L, et al
    Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial.
    Mult Scler. 2016 Aug 2. pii: 1352458516663033.
    PubMed     Text format     Abstract available


  195. VERMERSCH P, Smets L, Gold R
    Conclusions: Calls to action for improving the life of MS patients and their families.
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


  196. VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
    The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


  197. KALINCIK T, Kuhle J, Pucci E, Rojas JI, et al
    Data quality evaluation for observational multiple sclerosis registries.
    Mult Scler. 2016 Aug 1. pii: 1352458516662728.
    PubMed     Text format     Abstract available


  198. BOUTIERE C, Rey C, Zaaraoui W, Le Troter A, et al
    Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices.
    Mult Scler. 2016 Aug 1. pii: 1352458516661640.
    PubMed     Text format     Abstract available


  199. KHOURY SJ, Rochon J, Ding L, Byron M, et al
    ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Aug 1. pii: 1352458516662727.
    PubMed     Text format     Abstract available


  200. SCHREIBER K, Magyari M, Sellebjerg F, Iversen P, et al
    High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2016 Aug 1. pii: 1352458516661048.
    PubMed     Text format     Abstract available


  201. GROSS CC, Schulte-Mecklenbeck A, Hanning U, Posevitz-Fejfar A, et al
    Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.
    Mult Scler. 2016 Aug 1. pii: 1352458516662726.
    PubMed     Text format     Abstract available


    July 2016
  202. BUHLER U, Fleischer V, Luessi F, Rezk A, et al
    Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Mult Scler. 2016 Jul 19. pii: 1352458516658559.
    PubMed     Text format     Abstract available


  203. ONTANEDA D, Love TE
    Propensity methods for multiple sclerosis: The devil is in the details.
    Mult Scler. 2016 Jul 13. pii: 1352458516660390.
    PubMed     Text format    


  204. SBARDELLA E, Upadhyay N, Tona F, Prosperini L, et al
    Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.
    Mult Scler. 2016 Jul 13. pii: 1352458516657438.
    PubMed     Text format     Abstract available


    June 2016
  205. COFRE LIZAMA LE, Khan F, Lee PV, Galea MP, et al
    The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658137.
    PubMed     Text format     Abstract available


  206. SOELBERG SORENSEN P, Sellebjerg F
    Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658560.
    PubMed     Text format    


  207. MCKAY KA, Tremlett H, Patten SB, Fisk JD, et al
    Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    Mult Scler. 2016 Jun 29. pii: 1352458516657440.
    PubMed     Text format     Abstract available


  208. VACCHI L, Rocca MA, Meani A, Rodegher M, et al
    Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.
    Mult Scler. 2016 Jun 28. pii: 1352458516656809.
    PubMed     Text format     Abstract available


  209. NISHIHARA H, Shimizu F, Kitagawa T, Yamanaka N, et al
    Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655217.
    PubMed     Text format     Abstract available


  210. SETHI V, Nair G, Absinta M, Sati P, et al
    Slowly eroding lesions in multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655403.
    PubMed     Text format     Abstract available


  211. ROSJO E, Lossius A, Abdelmagid N, Lindstrom JC, et al
    Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516654310.
    PubMed     Text format     Abstract available


  212. MENON S, Zhu F, Shirani A, Oger J, et al
    Disability progression in aggressive multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516653273.
    PubMed     Text format     Abstract available


  213. BURTON JM
    Response to "Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis" by Knippenberg et al.
    Mult Scler. 2016 Jun 14. pii: 1352458516652951.
    PubMed     Text format    


  214. KNIPPENBERG S, Smolders J, van den Maegdenbergh M, Porro G, et al
    Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis.
    Mult Scler. 2016 Jun 14. pii: 1352458516652950.
    PubMed     Text format    


  215. NAISMITH RT
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.
    Mult Scler. 2016 Jun 8. pii: 1352458516644676.
    PubMed     Text format    


  216. MILLER AE
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.
    Mult Scler. 2016 Jun 8. pii: 1352458516649039.
    PubMed     Text format    


  217. GIOVANNONI G
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.
    Mult Scler. 2016 Jun 8. pii: 1352458516650737.
    PubMed     Text format    


  218. BUSCARINU MC, Cerasoli B, Annibali V, Policano C, et al
    Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.
    Mult Scler. 2016 Jun 6. pii: 1352458516652498.
    PubMed     Text format     Abstract available


  219. CALABRESE M, Castellaro M, Bertoldo A, De Luca A, et al
    Epilepsy in multiple sclerosis: The role of temporal lobe damage.
    Mult Scler. 2016 Jun 3. pii: 1352458516651502.
    PubMed     Text format     Abstract available


    May 2016
  220. FLEISCHER V, Groger A, Koirala N, Droby A, et al
    Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651503.
    PubMed     Text format     Abstract available


  221. LEE H, Narayanan S, Brown RA, Chen JT, et al
    Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516650992.
    PubMed     Text format     Abstract available


  222. VISTBAKKA J, Elovaara I, Lehtimaki T, Hagman S, et al
    Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651141.
    PubMed     Text format     Abstract available


  223. CONWAY DS, Thompson NR, Cohen JA
    Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
    Mult Scler. 2016 May 26. pii: 1352458516650512.
    PubMed     Text format     Abstract available


  224. UHER T, Havrdova E, Sobisek L, Krasensky J, et al
    Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Mult Scler. 2016 May 26. pii: 1352458516650525.
    PubMed     Text format     Abstract available


  225. BARONCINI D, Ghezzi A, Annovazzi PO, Colombo B, et al
    Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Mult Scler. 2016 May 26. pii: 1352458516650736.
    PubMed     Text format     Abstract available


  226. OTERO-ROMERO S, Sastre-Garriga J, Comi G, Hartung HP, et al
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Mult Scler. 2016 May 19. pii: 1352458516643600.
    PubMed     Text format     Abstract available


  227. LIU G, Zhang F, Jiang Y, Hu Y, et al
    Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways.
    Mult Scler. 2016 May 19. pii: 1352458516649038.
    PubMed     Text format     Abstract available


  228. GOLD R, Arnold DL, Bar-Or A, Hutchinson M, et al
    Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Mult Scler. 2016 May 19. pii: 1352458516649037.
    PubMed     Text format     Abstract available


  229. COSTA SL, Genova HM, DeLuca J, Chiaravalloti ND, et al
    Information processing speed in multiple sclerosis: Past, present, and future.
    Mult Scler. 2016 May 9. pii: 1352458516645869.
    PubMed     Text format     Abstract available


  230. BJORNEVIK K, Riise T, Benjaminsen E, Celius EG, et al
    Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
    Mult Scler. 2016 May 5. pii: 1352458516646863.
    PubMed     Text format     Abstract available


  231. MILLER AE
    Multiple sclerosis disease-modifying therapy and pregnancy.
    Mult Scler. 2016;22:715-6.
    PubMed     Text format    


    April 2016
  232. PAPATHEMELI D, Grafe R, Hildebrandt U, Zettl UK, et al
    Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler. 2016 Apr 26. pii: 1352458516645868.
    PubMed     Text format     Abstract available


  233. HUTCHINSON M
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.
    Mult Scler. 2016 Apr 22. pii: 1352458516646466.
    PubMed     Text format    


  234. BRENNER R
    All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
    Mult Scler. 2016 Apr 22. pii: 1352458516642855.
    PubMed     Text format    


  235. BROWNLEE WJ, Ciccarelli O
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
    Mult Scler. 2016 Apr 22. pii: 1352458516636474.
    PubMed     Text format    


  236. LUDWIN SK, Rao VT, Moore CS, Antel JP, et al
    Astrocytes in multiple sclerosis.
    Mult Scler. 2016 Apr 19. pii: 1352458516643396.
    PubMed     Text format     Abstract available


  237. SASTRE-GARRIGA J
    Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?
    Mult Scler. 2016 Apr 18. pii: 1352458516644677.
    PubMed     Text format     Abstract available


  238. VELDHUIJZEN VAN ZANTEN JJ, Pilutti LA, Duda JL, Motl RW, et al
    Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
    Mult Scler. 2016 Apr 12. pii: 1352458516644340.
    PubMed     Text format     Abstract available


  239. WESTERLIND H, Stawiarz L, Fink K, Hillert J, et al
    A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
    Mult Scler. 2016 Apr 12. pii: 1352458516643394.
    PubMed     Text format     Abstract available


  240. BEAUCHEMINA P, Carruthers R
    Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis.
    Mult Scler. 2016 Apr 11. pii: 1352458516643398.
    PubMed     Text format    


  241. KOCH-HENRIKSEN N, Magyari M, Sellebjerg F, Soelberg Sorensen P, et al
    A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Mult Scler. 2016 Apr 7. pii: 1352458516643393.
    PubMed     Text format     Abstract available


  242. STEWART T, Spelman T, Havrdova E, Horakova D, et al
    Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Mult Scler. 2016 Apr 7. pii: 1352458516643392.
    PubMed     Text format     Abstract available


  243. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2016 Apr 7. pii: 1352458516644058.
    PubMed     Text format     Abstract available


  244. UHER T, Vaneckova M, Sobisek L, Tyblova M, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Mult Scler. 2016 Apr 6. pii: 1352458516642314.
    PubMed     Text format     Abstract available


  245. MATOULA T, Nikolaou V, Marinos L, Katsavos S, et al
    Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
    Mult Scler. 2016 Apr 6. pii: 1352458516642032.
    PubMed     Text format    


  246. HARDY TA, Tobin WO, Lucchinetti CF
    Exploring the overlap between multiple sclerosis, tumefactive demyelination and Balo's concentric sclerosis.
    Mult Scler. 2016 Apr 1. pii: 1352458516641776.
    PubMed     Text format     Abstract available


  247. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue? Response to Feinstein.
    Mult Scler. 2016;22:575-6.
    PubMed     Text format    


  248. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Mult Scler. 2016;22:708-9.
    PubMed     Text format    


  249. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Text format     Abstract available


  250. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Text format     Abstract available


  251. FUJITA-NAKATA M, Tomioka R, Tanaka K, Nakanishi M, et al
    Intractable cough as characteristic symptom of neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016;22:576-7.
    PubMed     Text format    


  252. RADAELLI M, Moiola L, Sangalli F, Esposito F, et al
    Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Mult Scler. 2016;22:511-9.
    PubMed     Text format     Abstract available


  253. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Text format     Abstract available


    March 2016
  254. PATEL VP, Zambrana A, Walker LA, Herrmann N, et al
    Distraction adds to the cognitive burden in multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641208.
    PubMed     Text format     Abstract available


  255. STROHM T, Chaudhry B, Willis MA, Shook S, et al
    Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641774.
    PubMed     Text format     Abstract available


  256. CADAVID D, Cohen JA, Freedman MS, Goldman MD, et al
    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Mar 22. pii: 1352458516638941.
    PubMed     Text format     Abstract available


  257. NOVAKOVA L, Axelsson M, Khademi M, Zetterberg H, et al
    Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Mult Scler. 2016 Mar 21. pii: 1352458516639384.
    PubMed     Text format     Abstract available


  258. MIDAGLIA L, Juega Marino JM, Sastre-Garriga J, Rovira A, et al
    An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.
    Mult Scler. 2016 Mar 18. pii: 1352458516638557.
    PubMed     Text format     Abstract available


  259. HILZ MJ
    Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis.
    Mult Scler. 2016 Mar 18. pii: 1352458516638559.
    PubMed     Text format     Abstract available


  260. BECKER J, Rolfs A, Karabul N, Berlit P, et al
    D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic.
    Mult Scler. 2016 Mar 18. pii: 1352458516638747.
    PubMed     Text format     Abstract available


  261. PETRACCA M, Cordano C, Cellerino M, Button J, et al
    Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?
    Mult Scler. 2016 Mar 18. pii: 1352458516637679.
    PubMed     Text format     Abstract available


  262. ALBOR C, du Sautoy T, Kali Vanan N, Turner BP, et al
    Ethnicity and prevalence of multiple sclerosis in east London.
    Mult Scler. 2016 Mar 17. pii: 1352458516638746.
    PubMed     Text format     Abstract available


  263. OBERMANN M, Ruck T, Pfeuffer S, Baum J, et al
    Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Mar 15. pii: 1352458516638558.
    PubMed     Text format     Abstract available


  264. ZINGER A, Latham SL, Combes V, Byrne S, et al
    Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Mult Scler. 2016 Mar 1. pii: 1352458516636959.
    PubMed     Text format     Abstract available


  265. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed     Text format    


  266. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Text format     Abstract available


  267. COBO-CALVO A, Sepulveda M, Bernard-Valnet R, Ruiz A, et al
    Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.
    Mult Scler. 2016;22:312-9.
    PubMed     Text format     Abstract available


  268. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Text format     Abstract available


  269. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Text format     Abstract available


  270. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Text format     Abstract available


  271. JEONG IH, Park B, Kim SH, Hyun JW, et al
    Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
    Mult Scler. 2016;22:329-39.
    PubMed     Text format     Abstract available


    February 2016
  272. THIEL S, Langer-Gould A, Rockhoff M, Haghikia A, et al
    Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Mult Scler. 2016 Feb 26. pii: 1352458516634872.
    PubMed     Text format     Abstract available


  273. D'AMICO E, Leone C, Hayrettin T, Patti F, et al
    Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
    Mult Scler. 2016 Feb 26. pii: 1352458516632066.
    PubMed     Text format     Abstract available


  274. KIM SH, Kwak K, Jeong IH, Hyun JW, et al
    Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516636246.
    PubMed     Text format     Abstract available


  275. FIEST KM, Marrie RA, Jette N, Bennett DA, et al
    The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516634873.
    PubMed     Text format     Abstract available


  276. SUMOWSKI JF, Rocca MA, Leavitt VM, Riccitelli G, et al
    Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516630822.
    PubMed     Text format     Abstract available


  277. WANG Y, Bos SD, Harbo HF, Thompson WK, et al
    Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors.
    Mult Scler. 2016 Feb 26. pii: 1352458516635873.
    PubMed     Text format     Abstract available


  278. JEONG IH, Choi JY, Kim SH, Hyun JW, et al
    Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Feb 26. pii: 1352458516636247.
    PubMed     Text format     Abstract available


  279. CAVALLARI M, Palotai M, Glanz BI, Egorova S, et al
    Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Feb 26. pii: 1352458516635874.
    PubMed     Text format     Abstract available


  280. RAZAZ N, Tremlett H, Marrie RA, Joseph KS, et al
    Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children.
    Mult Scler. 2016 Feb 22. pii: 1352458516631037.
    PubMed     Text format     Abstract available


  281. JIANG H, Delgado S, Tan J, Liu C, et al
    Impaired retinal microcirculation in multiple sclerosis.
    Mult Scler. 2016 Feb 22. pii: 1352458516631035.
    PubMed     Text format     Abstract available


  282. SANAI SA, Saini V, Benedict RH, Zivadinov R, et al
    Aging and multiple sclerosis.
    Mult Scler. 2016 Feb 19. pii: 1352458516634871.
    PubMed     Text format     Abstract available


  283. PHE V, Pakzad M, Curtis C, Porter B, et al
    Urinary tract infections in multiple sclerosis.
    Mult Scler. 2016 Feb 18. pii: 1352458516633903.
    PubMed     Text format     Abstract available


  284. DECKER Y, Schomburg R, Nemeth E, Vitkin A, et al
    Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients.
    Mult Scler. 2016 Feb 16. pii: 1352458516631036.
    PubMed     Text format     Abstract available


  285. MOKKINK LB, Galindo-Garre F, Uitdehaag BM
    Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.
    Mult Scler. 2016 Feb 12. pii: 1352458516630821.
    PubMed     Text format     Abstract available


  286. SCALFARI A, Lederer C, Daumer M, Nicholas R, et al
    The relationship of age with the clinical phenotype in multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516630396.
    PubMed     Text format     Abstract available


  287. JARIUS S, Metz I, Konig FB, Ruprecht K, et al
    Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Mult Scler. 2016 Feb 11. pii: 1352458515622986.
    PubMed     Text format     Abstract available


  288. PASTO L, Portaccio E, Goretti B, Ghezzi A, et al
    The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516629559.
    PubMed     Text format     Abstract available


  289. PAKPOOR J, Wotton CJ, Schmierer K, Giovannoni G, et al
    Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
    Mult Scler. 2016 Feb 8. pii: 1352458515627205.
    PubMed     Text format     Abstract available


  290. BISECCO A, Caiazzo G, d'Ambrosio A, Sacco R, et al
    Fatigue in multiple sclerosis: The contribution of occult white matter damage.
    Mult Scler. 2016 Feb 4. pii: 1352458516628331.
    PubMed     Text format     Abstract available


  291. PRAVATA E, Zecca C, Sestieri C, Caulo M, et al
    Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.
    Mult Scler. 2016 Feb 4. pii: 1352458515625806.
    PubMed     Text format     Abstract available


  292. FAIVRE A, Robinet E, Guye M, Rousseau C, et al
    Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study.
    Mult Scler. 2016 Feb 2. pii: 1352458516628657.
    PubMed     Text format     Abstract available


  293. TAYLOR BV
    Modeling the course and outcomes of multiple sclerosis is statistical twaddle-Yes.
    Mult Scler. 2016;22:140-2.
    PubMed     Text format    


  294. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed     Text format    


  295. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Text format     Abstract available


  296. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Text format     Abstract available


  297. ABBOUD H, Petrak A, Mealy M, Sasidharan S, et al
    Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
    Mult Scler. 2016;22:185-92.
    PubMed     Text format     Abstract available


    January 2016
  298. LAULE C, Yung A, Pavolva V, Bohnet B, et al
    High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report.
    Mult Scler. 2016 Jan 27. pii: 1352458515624559.
    PubMed     Text format     Abstract available


  299. ZHOU Y, Zhu G, Charlesworth JC, Simpson S Jr, et al
    Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
    Mult Scler. 2016 Jan 27. pii: 1352458515626598.
    PubMed     Text format     Abstract available


  300. BEHRENS JR, Mertens S, Kruger T, Grobelny A, et al
    Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
    Mult Scler. 2016 Jan 26. pii: 1352458515625807.
    PubMed     Text format     Abstract available


  301. GEORGE IC, Sati P, Absinta M, Cortese IC, et al
    Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis.
    Mult Scler. 2016 Jan 14. pii: 1352458515624975.
    PubMed     Text format     Abstract available


  302. ZORNER B, Filli L, Reuter K, Kapitza S, et al
    Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Mult Scler. 2016 Jan 13. pii: 1352458515622695.
    PubMed     Text format     Abstract available


  303. KHALIL M, Renner A, Langkammer C, Enzinger C, et al
    Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Mult Scler. 2016 Jan 13. pii: 1352458515624560.
    PubMed     Text format     Abstract available


  304. OHRFELT A, Axelsson M, Malmestrom C, Novakova L, et al
    Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Mult Scler. 2016 Jan 11. pii: 1352458515624558.
    PubMed     Text format     Abstract available


  305. PANDIT L, Ban M, Beecham AH, McCauley JL, et al
    European multiple sclerosis risk variants in the south Asian population.
    Mult Scler. 2016 Jan 11. pii: 1352458515624270.
    PubMed     Text format     Abstract available


  306. BHARGAVA P, Calabresi PA
    Metabolomics in multiple sclerosis.
    Mult Scler. 2016 Jan 11. pii: 1352458515622827.
    PubMed     Text format     Abstract available


  307. HOJJAT SP, Cantrell CG, Vitorino R, Feinstein A, et al
    Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Jan 11. pii: 1352458515622696.
    PubMed     Text format     Abstract available


  308. NIELSEN NM, Harpsoe MC, Simonsen J, Stenager E, et al
    Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.
    Mult Scler. 2016 Jan 8. pii: 1352458515621623.
    PubMed     Text format     Abstract available


  309. HASSELMANN H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, et al
    Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression.
    Mult Scler. 2016 Jan 8. pii: 1352458515622826.
    PubMed     Text format     Abstract available


  310. COMABELLA M
    Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled - MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016 Jan 7. pii: 1352458515623863.
    PubMed     Text format     Abstract available


  311. MEIJER KA, Muhlert N, Cercignani M, Sethi V, et al
    White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515622694.
    PubMed     Text format     Abstract available


  312. MORI F, Nistico R, Nicoletti CG, Zagaglia S, et al
    RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515621796.
    PubMed     Text format     Abstract available


  313. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed     Text format    


  314. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed     Text format    


  315. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed     Text format    


  316. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed     Text format    


    December 2015
  317. RAZAZ N, Joseph KS, Boyce WT, Guhn M, et al
    Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health.
    Mult Scler. 2015 Dec 18. pii: 1352458515621624.
    PubMed     Text format     Abstract available


  318. JONKMAN LE, Fleysher L, Steenwijk MD, Koeleman JA, et al
    Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515620499.
    PubMed     Text format     Abstract available


  319. CONTE A, Li Voti P, Pontecorvo S, Quartuccio ME, et al
    Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515619780.
    PubMed     Text format     Abstract available


  320. STRAUDI S, Fanciullacci C, Martinuzzi C, Pavarelli C, et al
    The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2015 Dec 10. pii: 1352458515620933.
    PubMed     Text format     Abstract available


  321. MISTRY N, Abdel-Fahim R, Samaraweera A, Mougin O, et al
    Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
    Mult Scler. 2015 Dec 10. pii: 1352458515616700.
    PubMed     Text format     Abstract available


    November 2015
  322. SCHEEPE JR, Wong YY, van Pelt ED, Ketelslegers IA, et al
    Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
    Mult Scler. 2015 Nov 20. pii: 1352458515618541.
    PubMed     Text format     Abstract available


  323. KAPPOS L, De Stefano N, Freedman MS, Cree BA, et al
    Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Nov 19. pii: 1352458515616701.
    PubMed     Text format     Abstract available


  324. STEENWIJK MD, Vrenken H, Jonkman LE, Daams M, et al
    High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis.
    Mult Scler. 2015 Nov 12. pii: 1352458515615953.
    PubMed     Text format     Abstract available


  325. FOK A, Williams T, McLean CA, Butler E, et al
    Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515618020.
    PubMed     Text format     Abstract available


  326. WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
    Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515615225.
    PubMed     Text format     Abstract available


  327. YAMASAKI R, Matsushita T, Fukazawa T, Yokoyama K, et al
    Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Nov 12. pii: 1352458515617248.
    PubMed     Text format     Abstract available


    May 2015
  328. LULU S, Graves J, Waubant E
    Menarche increases relapse risk in pediatric multiple sclerosis.
    Mult Scler. 2015 May 6. pii: 1352458515581873.
    PubMed     Text format     Abstract available


  329. GREENBERG BM
    Placebo studies should not be undertaken in NMO--No.
    Mult Scler. 2015;21:691-3.
    PubMed     Text format    


  330. WEINSHENKER BG
    Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary.
    Mult Scler. 2015;21:693-4.
    PubMed     Text format    


  331. PALACE J
    Placebo studies should not be undertaken in NMO--Yes.
    Mult Scler. 2015;21:689-91.
    PubMed     Text format    


  332. IORIO R, Rindi G, Erra C, Damato V, et al
    Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
    Mult Scler. 2015;21:791-4.
    PubMed     Text format     Abstract available


  333. LONGBRAKE EE, Cross AH
    Dimethyl fumarate associated lymphopenia in clinical practice.
    Mult Scler. 2015;21:796-7.
    PubMed     Text format    


  334. SASTRE-GARRIGA J, Tur C, Pareto D, Vidal-Jordana A, et al
    Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Mult Scler. 2015;21:749-56.
    PubMed     Text format     Abstract available


  335. VIDAL-JORDANA A, Tintore M, Tur C, Perez-Miralles F, et al
    Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Mult Scler. 2015;21:780-5.
    PubMed     Text format     Abstract available


  336. HYUN JW, Kim SH, Huh SY, Kim W, et al
    Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
    Mult Scler. 2015;21:710-7.
    PubMed     Text format     Abstract available


  337. COMI G, Gold R, Dahlke F, Sinha A, et al
    Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Mult Scler. 2015;21:786-90.
    PubMed     Text format     Abstract available


    April 2015
  338. MUSELLA A, Mandolesi G, Mori F, Gentile A, et al
    Linking synaptopathy and gray matter damage in multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515581875.
    PubMed     Text format    


  339. SINDIC C, Edan G
    Richard E Gonsette (1929-2014).
    Mult Scler. 2015;21:540.
    PubMed     Text format    


  340. TANAKA M, Kinoshita M, Tanaka K
    Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders.
    Mult Scler. 2015;21:669.
    PubMed     Text format    


  341. PEAUREAUX D, Pignolet B, Biotti D, Bucciarelli F, et al
    Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Mult Scler. 2015;21:671-2.
    PubMed     Text format    


  342. IKEDA K, Kiyota N, Kuroda H, Sato DK, et al
    Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.
    Mult Scler. 2015;21:656-9.
    PubMed     Text format     Abstract available


  343. PESCHL P, Reindl M, Schanda K, Sospedra M, et al
    Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.
    Mult Scler. 2015;21:651-5.
    PubMed     Text format     Abstract available


  344. ELLIS R, Brown S, Boggild M
    Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Mult Scler. 2015;21:642-5.
    PubMed     Text format     Abstract available


  345. ARRAMBIDE G, Tur C, Montalban X
    Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.
    Mult Scler. 2015;21:660-1.
    PubMed     Text format    


  346. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue?
    Mult Scler. 2015;21:376-81.
    PubMed     Text format     Abstract available


  347. LEE J, Jeong SH, Park SM, Sohn EH, et al
    Anti-aquaporin-4 antibody-positive dorsal midbrain syndrome.
    Mult Scler. 2015;21:477-80.
    PubMed     Text format     Abstract available


  348. VISWANATHAN S
    Wasted tongue in neuromyelitis optica spectrum disorders due to hypoglossal nerve involvement.
    Mult Scler. 2015;21:488-91.
    PubMed     Text format     Abstract available


    March 2015
  349. ROBERG BL, Bruce JM
    Reconsidering outdoor temperature and cognition in multiple sclerosis.
    Mult Scler. 2015 Mar 3. pii: 1352458515575172.
    PubMed     Text format     Abstract available


    January 2015
  350. HAUSER SL
    The Charcot Lecture | beating MS: a story of B cells, with twists and turns.
    Mult Scler. 2015;21:8-21.
    PubMed     Text format     Abstract available


  351. VAN SCHEPENDOM J, D'hooghe MB, Cleynhens K, D'hooge M, et al
    Reduced information processing speed as primum movens for cognitive decline in MS.
    Mult Scler. 2015;21:83-91.
    PubMed     Text format     Abstract available


  352. NILSAGARD Y, Gunn H, Freeman J, Hoang P, et al
    Falls in people with MS--an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States.
    Mult Scler. 2015;21:92-100.
    PubMed     Text format     Abstract available


    August 2014
  353. AKHTAR S, Alroughani R, Al-Shammari A, Al-Abkal J, et al
    Month of birth and risk of multiple sclerosis in Kuwait: A population-based registry study.
    Mult Scler. 2014 Aug 4. pii: 1352458514541578.
    PubMed     Text format     Abstract available


    July 2014
  354. FRNDAK SE, Kordovski VM, Cookfair D, Rodgers JD, et al
    Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations.
    Mult Scler. 2014 Jul 28. pii: 1352458514540971.
    PubMed     Text format     Abstract available


  355. BOSMA L, Sonder J, Kragt J, Polman C, et al
    Detecting clinically-relevant changes in progressive multiple sclerosis.
    Mult Scler. 2014 Jul 10. pii: 1352458514540969.
    PubMed     Text format     Abstract available


    June 2014
  356. SCHIPPLING S, Balk L, Costello F, Albrecht P, et al
    Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.
    Mult Scler. 2014 Jun 16. pii: 1352458514538110.
    PubMed     Text format     Abstract available


  357. KRYSKO KM, Ivers NM, Young J, O'Connor P, et al
    Identifying individuals with multiple sclerosis in an electronic medical record.
    Mult Scler. 2014 Jun 12. pii: 1352458514538334.
    PubMed     Text format     Abstract available


    May 2014
  358. ROTONDI M, Bergamaschi R, Chiovato L
    Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-beta and glatiramer acetate?
    Mult Scler. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: